Ramón García Sanz-rekin lankidetzan egindako argitalpenak (24)

2024

  1. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

  2. Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry

    Haematologica

2023

  1. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

    Blood Cancer Journal, Vol. 13, Núm. 1

  2. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

    Cancers, Vol. 15, Núm. 2

2022

  1. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

    Cancers, Vol. 14, Núm. 23

  2. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

  3. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

2020

  1. Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design

    PLoS ONE, Vol. 15, Núm. 1

  2. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  3. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  4. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

  5. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

2018

  1. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

    Haematologica

  2. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

    Blood cancer journal, Vol. 8, Núm. 12, pp. 117

2010

  1. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma

    Clinical Cancer Research, Vol. 16, Núm. 12, pp. 3260-3269

  2. Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología

    Medicina Clinica, Vol. 134, Núm. 6, pp. 268-278

2008

  1. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression

    Haematologica, Vol. 93, Núm. 4, pp. 560-565

2006

  1. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study

    Blood, Vol. 108, Núm. 7, pp. 2165-2172

  2. Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma

    Hematological Oncology, Vol. 24, Núm. 4, pp. 205-211